Listen to this article |
While answering a question for a DrugPatentWatch user, the question arose of technologies the NIH has licensed.
It turns out that they keep a list on their website, so I went ahead and converted it from PDF for easier reading.
Let me know if a more detailed list would be of interest and I’ll see what I can do:
Table of Contents
NIH-Licensed Technologies:
Technology: Vaccine For Dengue Virus
Licensee: Merck Sharp & Dohme Corp.
Exclusivity: Exclusive
Territory: Other
FY: 2015
License No: L-001-2015
Tech No: E-171-1988
Technology: MAGE Family Of Cancer/testis (C/T) Antigen Presented By Multiple HLA Class I Alleles.
Licensee: Kite Pharma, Inc.
Exclusivity: Exclusive
Territory: Worldwide
FY: 2016
License No: L-002-2016
Tech No: E-266-2011
Technology: Anti-HERV-K Envelope Antibody And Uses Thereof
Licensee: Geneuro SA
Exclusivity: Exclusive
Territory: Worldwide
FY: 2019
License No: L-002-2019
Tech No: E-088-2018
Technology: Cerclage Locking Device And Delivery System
Licensee: Transmural Systems, LLC
Exclusivity: Exclusive
Territory: Worldwide
FY: 2016
License No: L-003-2016
Tech No: E-048-2009
Technology: Structure-based Stabilization Of The RSV F Glycoprotein In Its Prefusion Conformation
Licensee: Calder Biosciences Inc.
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2020
License No: L-003-2020
Tech No: E-081-2013
Technology: Catalytic Domains Of Beta (1,4)-Galactosyltransferase I Having Altered Donor And Acceptor Specificities Domains, That Promote In Vitro Protein Folding And Methods For Their Use
Licensee: Life Technologies Corporation
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2007
License No: L-004-2007
Tech No: E-230-2002
Technology: Evans Blue Modified Small Molecule Based Prostate-specific Membrane Antigen (PSMA) Radiotherapy
Licensee: Sinotau Pharmaceutical Group
Exclusivity: Exclusive
Territory: Worldwide
FY: 2019
License No: L-004-2019
Tech No: E-054-2018
Technology: Ocular Therapeutic Agent Delivery Devices And Methods For Making And Using Such Devices
Licensee: North Carolina State University (NCSU)
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2013
License No: L-007-2013
Tech No: E-241-1999
Technology: Direct Cell Target Analysis
Licensee: xMD Diagnostics, LLC
Exclusivity: Exclusive
Territory: Worldwide
FY: 2015
License No: L-008-2015
Tech No: E-113-2003
Technology: Nucleoside Agonists Of Adenosine Receptors
Licensee: Bio-Techne Ltd
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2020
License No: L-008-2020
Tech No: E-022-2019
Technology: Zap70 Protein Expression in Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) and Likely Mantle Cell Lymphoma (MCL)…
Licensee: Dako Denmark A/S
Exclusivity: Nonexclusive
Territory: Other
FY: 2006
License No: L-011-2006
Tech No: E-091-2002
Technology: ACQUIRED IMMUNE DEFICIENCY SYNDROME (AIDS) VIRAL ENVELOPE PRO- TEIN AND METHOD OF TESTING FOR AIDS
Licensee: Abbott Laboratories, Inc.
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 1984
License No: L-015-1984
Tech No: E-722-1984
Technology: A Novel System For The Complete Removal Of All Mucus From
Licensee: Endoclear LLC
Exclusivity: Exclusive
Territory: Worldwide
FY: 2012
License No: L-015-2012
Tech No: E-061-2004
Technology: HUMAN GENE RELATED TO BUT DISTINCT FROM EGF RECEPTOR GENE (erbB-2)
Licensee: Schering AG
Exclusivity: Nonexclusive
Territory: US
FY: 1989
License No: L-017-1989
Tech No: E-555-1985
Technology: Use Of Roseomonas Species To Treat Eczematous Skin Disease
Licensee: Forte Biosciences Inc.
Exclusivity: Exclusive
Territory: Worldwide
FY: 2018
License No: L-018-2018
Tech No: E-099-2016
Technology: CHONDROPSIN-CLASS ANTITUMOR V-ATPASE INHIBITOR COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF.
Licensee: Australian Institute of Marine Science
Exclusivity: Exclusive
Territory: Worldwide
FY: 2013
License No: L-019-2013
Tech No: E-191-2002
Technology: Antibodies and Other Ligands Directed Against KIR2DL4 Receptor For Production of Interferon Gamma
Licensee: EXBIO Praha
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2010
License No: L-021-2010
Tech No: E-255-2000
Technology: The Development And Use Of Vaccines (Non-Yeast, Non-Poxvirus Based) For The Prevention And/or Therapy Of Human Cancer
Licensee: Etubics Corporation
Exclusivity: Exclusive
Territory: Worldwide
FY: 2017
License No: L-022-2017
Tech No: E-055-2011
Technology: MELANOMA ANTIGENS AND THEIR USE IN DIAGNOSTIC AND THERAPEUTIC METHODS
Licensee: Signet Laboratories, Inc.
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 1997
License No: L-024-1997
Tech No: E-057-1994
Technology: CONVECTION-ENHANCED DRUG DELIVERY
Licensee: NeoPharm, Inc.
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2006
License No: L-024-2006
Tech No: E-173-1992
Technology: MUTANT AEQUOREA VICTORIA FLUORESCENT PROTEINS HAVING INCREASED CELLULAR FLUORESCENCE
Licensee: Carolina Biological Supply Company
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2004
License No: L-025-2004
Tech No: E-186-1995
Technology: Geldanamycin Derivative And Method Of Treating Cancer Using Same
Licensee: Tocris Bioscience
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2007
License No: L-025-2007
Tech No: E-050-2000
Technology: CRYSTAL FORMS AND METHODS OF SYNTHESIS OF (2R, 6R)-HYDROXYNORKETAMINE AND (2S, 6S)-HYDROXYNORKETAMINE
Licensee: Tocris Bioscience
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2017
License No: L-025-2017
Tech No: E-116-2016
Technology: RECOMBINANT PSEUDOMONAS EXOTOXINS: CONSTRUCTION OF AN ACTIVE IMMUNOTOXIN WITH LOW SIDE EFFECTS
Licensee: MedImmune, Inc.
Exclusivity: Exclusive
Territory: Worldwide
FY: 2005
License No: L-026-2005
Tech No: E-385-1986
Technology: Use Of The Selective Progesterone Receptor Modulator CDB-2914 For Treating Uterine Leiomyomata And Stopping Bleeding In Patients Afflicted With Uterine Leiomyomata
Licensee: PregLem, SA
Exclusivity: Exclusive
Territory: Foreign
FY: 2013
License No: L-026-2013
Tech No: E-057-2008
Technology: Computer-aided Diagnosis Of Prostate Cancer In Multi-parametric MRI
Licensee: Scanmed LLC
Exclusivity: Exclusive
Territory: Worldwide
FY: 2018
License No: L-028-2018
Tech No: E-183-2016
Technology: Novel Monoclonal Antibodies To Ebolavirus Glycoprotein
Licensee: Ridgeback Biotherapeutics
Exclusivity: Exclusive
Territory: Worldwide
FY: 2019
License No: L-028-2019
Tech No: E-045-2015
Technology: SEROLOGICAL DETECTION OF ANTIBODIES TO HTLV-III IN SER PATIENTS WITH AIDS AND PRE-AIDS CONDITIONS
Licensee: Genelabs
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 1993
License No: L-029-1993
Tech No: E-317-1984
Technology: Beta1-insensitive T2 Magnetization Preparation Of MR Imaging At High Field
Licensee: Koninklijke Philips Electronics N.V.
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2012
License No: L-029-2012
Tech No: E-073-2005
Technology: Substituted Bicyclic Heteroaryl Inhibitors Of Bromodomain-containing Protein BRD4
Licensee: ConverGene, LLC
Exclusivity: Exclusive
Territory: Worldwide
FY: 2017
License No: L-030-2017
Tech No: E-004-2016
Technology: Immunogenic Peptides And Peptide Derivatives For Prostate And Breast Cancer Treatment
Licensee: Midissia Therapeutics
Exclusivity: Exclusive
Territory: Worldwide
FY: 2017
License No: L-032-2017
Tech No: E-116-2003
Technology: Recombinant Vaccines for Influenza and Hepatitis B Virus
Licensee: Imanis Life Sciences, LLC
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2015
License No: L-034-2015
Tech No: E-552-1982
Technology: Recombinant Vaccines for Influenza and Hepatitis B Virus
Licensee: Helocyte, Inc.
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2020
License No: L-034-2020
Tech No: E-552-1982
Technology: The Development And Use Of A Recombinant Brachyury Saccharomyces Cerevisiae (yeast) Vaccine For The Prevention And/or Therapy Of Human Cancer
Licensee: GlobeImmune, Inc.
Exclusivity: Exclusive
Territory: Worldwide
FY: 2012
License No: L-036-2012
Tech No: E-056-2011
Technology: Transauricular Intrapericardial Tricuspid Annuloplasty
Licensee: Cook Medical Technologies LLC
Exclusivity: Exclusive
Territory: Worldwide
FY: 2018
License No: L-036-2018
Tech No: E-027-2013
Technology: Cloned Genome of Infectious Hepatitis C Virus of Genotype 2a and Uses Thereof
Licensee: Apath, LLC
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2006
License No: L-037-2006
Tech No: E-100-1999
Technology: DEVELOPMENT OF MUTATIONS USEFUL FOR ATTENUATING
DENGUE VIRUSES AND CHIMERIC DENGUE VIRUSES
Licensee: Medigen Vaccine Biologics Corp
Exclusivity: Nonexclusive
Territory: Foreign
FY: 2017
License No: L-046-2017
Tech No: E-120-2001
Technology: ACQUIRED IMMUNE DEFICIENCY SYNDROME (AIDS) VIRAL ENVELOPE PROTEIN AND METHOD OF TESTING FOR AIDS
Licensee: Chembio Diagnostic Systems, Inc.
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2006
License No: L-047-2006
Tech No: E-317-1984
Technology: Methods and composition For The Promotion of Hair growth Utilizing Act in Binding Peptides
Licensee: Lee’s Pharmaceutical (Hong Kong) Ltd.
Exclusivity: Exclusive
Territory: Foreign
FY: 2003
License No: L-048-2003
Tech No: E-053-2002
Technology: Identification And Characterization Of HLA-A24 Agonist Epitopes Of MUC1-Oncoprotein
Licensee: PDS Biotechnology Corporation
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2015
License No: L-048-2015
Tech No: E-520-2013
Technology: Enhance Recovery Of Voluntary Swallowing Using Patient Control Of Vibro-tactile Stimulation To The Neck In Persons With Dysphagia Resulting From A Neurological Diseases Or Disorders
Licensee: Passy-Muir, Inc.
Exclusivity: Exclusive
Territory: Worldwide
FY: 2011
License No: L-050-2011
Tech No: E-251-2005
Technology: JANUS FAMILY KINASES AND IDENTIFICATION OF IMMUNE MODULATORS (JAK-3)
Licensee: Cell Signaling Technology, Inc.
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2013
License No: L-051-2013
Tech No: E-094-1994
Technology: Peptides Having Anti-Inflammatory Properties
Licensee: Riptide Bioscience, Inc
Exclusivity: Exclusive
Territory: Worldwide
FY: 2017
License No: L-051-2017
Tech No: E-242-2015
Technology: Selection Of CD8+ PD-1+ Or CD8+ TIM-3+ Cells From Peripheral Blood Of Cancer Patients Enriches For Tumor-Reactive Cells That Can Be Used For Adoptive Transfer In The Treatment Of Cancer
Licensee: MedGene Therapeutics, Inc.
Exclusivity: Exclusive
Territory: Worldwide
FY: 2018
License No: L-052-2018
Tech No: E-085-2013
Technology: Engineered CH2 Domain Antibodies (nanoCbodies)
Licensee: Research Corporation Technologies, Inc. (RCT)
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2010
License No: L-054-2010
Tech No: E-003-2007
Technology: Glucocerebrosidase Activators As A Treatment For Gaucher Disease
Licensee: Lysosomal Therapeutics, Inc.
Exclusivity: Exclusive
Territory: Other
FY: 2015
License No: L-055-2015
Tech No: E-257-2010
Technology: A Rapid High Efficacy Conjugation Method For Production Of Polysaccharide-Protein Conjugate Vaccines
Licensee: Program for Appropriate Tech. in Health
Exclusivity: Nonexclusive
Territory: Foreign
FY: 2004
License No: L-057-2004
Tech No: E-301-2003
Technology: Uses Of Cyclodextrin And Cyclodextrin In Combination With Vitamin E For The Treatment Of All Lysosomal Storage Diseases
Licensee: Vtesse, Inc.
Exclusivity: Exclusive
Territory: Worldwide
FY: 2015
License No: L-057-2015
Tech No: E-050-2012
Technology: Geldanamycin Derivative And Method Of Treating Cancer Using Same
Licensee: Millipore Sigma
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2016
License No: L-057-2016
Tech No: E-050-2000
Technology: COMPOSITIONS AND METHODS FOR IDENTIFYING AND TESTING TYROSINE KINASE SUBSTRATES AND THEIR AGONISTS AND ANTAGONISTS
Licensee: Cell Signaling Technology, Inc.
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2010
License No: L-059-2010
Tech No: E-010-1998
Technology: Chimpaneze Monoclonal Antibodies That Neutralizes Vaccinia Virus (and Possibly Othe Pox Viruses)
Licensee: BioFactura, Inc.
Exclusivity: Exclusive
Territory: Worldwide
FY: 2013
License No: L-061-2013
Tech No: E-145-2004
Technology: The Enhancer Elements Upstream Of The Human G6PC Minimal Promoter Are Necessary For Efficient Hepatic G6PC Expression
Licensee: Dimension Therapeutics, Inc.
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2019
License No: L-061-2019
Tech No: E-552-2013
Technology: Anti-Tubercular Drug:
Licensee: Sequella, Inc.
Exclusivity: Exclusive
Territory: Worldwide
FY: 2006
License No: L-063-2006
Tech No: E-031-2004
Technology: HUMAN GENE RELATED TO BUT DISTINCT FROM EGF RECEPTOR GENE (erbB-2)
Licensee: Epitomics, Inc.
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2011
License No: L-063-2011
Tech No: E-555-1985
Technology: Production of Adeno-Associated Virus in Insect Cells
Licensee: BioMarin Pharmaceutical Inc.
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2015
License No: L-063-2015
Tech No: E-325-2001
Technology: IMMUNOTOXIN WITH IN-VIVO T CELL SUPPRESSANT ACTIVITY
Licensee: Angimmune LLC
Exclusivity: Exclusive
Territory: Worldwide
FY: 2010
License No: L-064-2010
Tech No: E-012-1991
Technology: Zap70 Protein Expression in Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) and Likely Mantle Cell Lymphoma (MCL)…
Licensee: Epitomics, Inc.
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2011
License No: L-064-2011
Tech No: E-091-2002
Technology: A Non-Steroidal Anti-Inflammatory Drug Related Gene (NAG-1) And Secreted Protein That Has Anti-Tumorigenic Properties
Licensee: Millipore Sigma
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2001
License No: L-065-2001
Tech No: E-170-2000
Technology: MOLECULAR CLONES OF HIV 1 AND USES THEREOF
Licensee: Becton, Dickinson and Company
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2009
License No: L-066-2009
Tech No: E-062-1990
Technology: Use Of Viral Like Particles (VLPs) In The Development Of A Preventive Vaccine Against Chikungunya
Licensee: The Native Antigen Company
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2020
License No: L-066-2020
Tech No: E-004-2009
Technology: The Ability Of Novel Yeast-MUC1 Constructs To Mature Human Dendritic Cells (DCs) And Activate Human T Cells
Licensee: GlobeImmune, Inc.
Exclusivity: Exclusive
Territory: Worldwide
FY: 2012
License No: L-067-2012
Tech No: E-289-2011
Technology: Combined Growth Factor-Deleted and Thymidine Kinase-Deleted Vaccinia Virus Vector
Licensee: Jennerex Biotherapeutics Inc.
Exclusivity: Exclusive
Territory: Worldwide
FY: 2004
License No: L-068-2004
Tech No: E-181-1999
Technology: Multivalent Human-Bovine Rotavirus Vaccine
Licensee: Fundacao Butantan
Exclusivity: Exclusive
Territory: Foreign
FY: 2005
License No: L-068-2005
Tech No: E-015-1998
Technology: Real-Time, Interactive Volumetric Magnetic Resonance Imaging
Licensee: Surgi Vision, Inc.
Exclusivity: Nonexclusive
Territory: Other
FY: 2009
License No: L-069-2009
Tech No: E-082-2001
Technology: Multivalent Human-Bovine Rotavirus Vaccine
Licensee: Beijing Minhai Biotechnology Co., Ltd.
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2010
License No: L-069-2010
Tech No: E-015-1998
Technology: GITR Ligand And Antibodies And Uses Thereof
Licensee: BioLegend, Inc.
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2014
License No: L-069-2014
Tech No: E-229-2003
Technology: A Synthetic Methylmalonyl-CoA Mutase Transgene For The Treatment Of Mut Class Methylmalonic Acidemia (MMA)
Licensee: LogicBio Therapeutics, Inc.
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2019
License No: L-069-2019
Tech No: E-243-2012
Technology: Coil For Magnetic Stimulation and Methods For Using The Same
Licensee: Brainsway, Inc.
Exclusivity: Exclusive
Territory: Worldwide
FY: 2003
License No: L-070-2003
Tech No: E-223-2000
Technology: Coil For Magnetic Stimulation and Methods For Using The Same
Licensee: Brainsway, Inc.
Exclusivity: Exclusive
Territory: Worldwide
FY: 2003
License No: L-070-2003
Tech No: E-223-2000
Technology: Use Of Viral Like Particles (VLPs) In The Development Of A Preventive Vaccine Against Chikungunya
Licensee: PaxVax, Inc.
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2016
License No: L-070-2016
Tech No: E-004-2009
Technology: DNA ENCODING A GROWTH FACTOR SPECIFIC FOR EPITHELIAL CELLS (KGF)
Licensee: Invitrogen Corporation
Exclusivity: Nonexclusive
Territory: US
FY: 1993
License No: L-071-1993
Tech No: E-009-1989
Technology: Human Monoclonal Antibody Against Mesothelin
Licensee: Atara Biotherapeutics Inc.
Exclusivity: Exclusive
Territory: Worldwide
FY: 2019
License No: L-071-2019
Tech No: E-079-2008
Technology: Antibodies and Other Ligands Directed Against KIR2DL4 Receptor For Production of Interferon Gamma
Licensee: BioLegend, Inc.
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2009
License No: L-072-2009
Tech No: E-255-2000
Technology: Adult Human Dental Pulp Stem Cells In Vitro and In Vivo
Licensee: Angioblast, Inc.
Exclusivity: Exclusive
Territory: Worldwide
FY: 2010
License No: L-072-2010
Tech No: E-233-2000
Technology: ApoC-llA Mimetic Peptides That Antagonize ApoC-111
Licensee: Corvidia Therapeutics, Inc.
Exclusivity: Exclusive
Territory: Worldwide
FY: 2018
License No: L-072-2018
Tech No: E-134-2017
Technology: AAV5 AND USES THEREOF
Licensee: Vector Biolabs
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2012
License No: L-074-2012
Tech No: E-127-1998
Technology: Device For Closure Of Transvascular Or Transcameral Access Ports
Licensee: Transmural Systems, LLC
Exclusivity: Exclusive
Territory: Worldwide
FY: 2016
License No: L-074-2016
Tech No: E-124-2014
Technology: Structure-based Stabilization Of The RSV F Glycoprotein In Its Prefusion Conformation
Licensee: China National Biotec Group Company
Limited
Exclusivity: Nonexclusive
Territory: Foreign
FY: 2020
License No: L-074-2020
Tech No: E-081-2013
Technology: Thymic Stromal Lymphopoietin Receptor (TSLPR) Chimeric Antigen Receptors
Licensee: Lentigen Corporation
Exclusivity: Exclusive
Territory: Worldwide
FY: 2016
License No: L-075-2016
Tech No: E-008-2014
Technology: Design Of (N)-Methanocarba Adenosine 5’Uronamides As Species-Independent A3 Receptor-Selective Agonists
Licensee: BioIntervene Inc.
Exclusivity: Exclusive
Territory: Worldwide
FY: 2017
License No: L-075-2017
Tech No: E-140-2008
Technology: Methods for Preparing Bacillus Anthracis Protective Antigen For Use In Vaccines (including use of BH445)
Licensee: Emergent Product Development
Gaithersburg, Inc.
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2008
License No: L-076-2008
Tech No: E-023-2002
Technology: Methods for Preparing Bacillus Anthracis Protective Antigen For Use In Vaccines (including use of BH445)
Licensee: Emergent Product Development
Gaithersburg, Inc.
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2008
License No: L-076-2008
Tech No: E-023-2002
Technology: IDENTIFICATION OF TRP-2 AS A NEW HUMAN TUMOR ANTIGEN RECOGNIZED BY CYTOTOXIC T LYMPHOCYTES
Licensee: Scancell Ltd.
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2010
License No: L-076-2010
Tech No: E-183-1996
Technology: T Cell Receptor Targeting An HLA-A2 Restricted Epitope Of Human Papillomavirus-16 E6
Licensee: Kite Pharma, Inc.
Exclusivity: Exclusive
Territory: Worldwide
FY: 2015
License No: L-077-2015
Tech No: E-495-2013
Technology: Recombinant Vaccines for Influenza and Hepatitis B Virus
Licensee: CEVA Biomune – Biomune Company
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2011
License No: L-078-2011
Tech No: E-552-1982
Technology: SCALABLE PURIFICATION OF AAV2, AAV4 OR AAV5 USING ION-EXCHANGE CHROMATOGRAPHY
Licensee: Spark Therapeutics, Inc.
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2015
License No: L-078-2015
Tech No: E-308-2001
Technology: Functions And Targets Of Therapeutic MicroRNAs To Treat Cancer
Licensee: miRecule, Inc.
Exclusivity: Exclusive
Territory: Worldwide
FY: 2018
License No: L-078-2018
Tech No: E-043-2016
Technology: Methods and Devices for Isolation and Analysis of Cellular Protein Content
Licensee: Theranostics Health, LLC
Exclusivity: Exclusive
Territory: Worldwide
FY: 2008
License No: L-079-2008
Tech No: E-261-1998
Technology: A Gene Expression Biomarker Panel For Diagnosis Of Acute Ischemic Stroke
Licensee: VuEssence, Inc.
Exclusivity: Co-Exclusive
Territory: Worldwide
FY: 2017
License No: L-079-2017
Tech No: E-023-2010
Technology: CHIMERIC DENGUE VIRUSES
Licensee: Panacea Biotech Ltd.
Exclusivity: Nonexclusive
Territory: Other
FY: 2006
License No: L-080-2006
Tech No: E-170-1991
Technology: Human Gene Critical To Fertility
Licensee: OriGene Technologies
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2009
License No: L-080-2009
Tech No: E-239-2000
Technology: A Coincidence Reporter Gene-system For High Throughput Screening
Licensee: Promega Corporation
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2015
License No: L-080-2015
Tech No: E-300-2012
Technology: Phantoms For Calibration Of Magnetic Resonance Diffusion Measurements.
Licensee: Computerized Imaging Reference
Systems, Inc. (CIRS)
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2020
License No: L-080-2020
Tech No: E-249-2008
Technology: SEROLOGICAL DETECTION OF ANTIBODIES TO HTLV-III IN SER PATIENTS WITH AIDS AND PRE-AIDS CONDITIONS
Licensee: ZeptoMetrix LLC
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 1996
License No: L-082-1996
Tech No: E-317-1984
Technology: Methanocarba Analogues of Purine And Pyrimidine Nucleosides And Nucleotides as Ligands For P1 And P2 Receptors.
Licensee: Cornovus Pharmaceuticals, Inc.
Exclusivity: Exclusive
Territory: Worldwide
FY: 2013
License No: L-082-2013
Tech No: E-176-1999
Technology: Agents that Bind To And Inhibit Human Cytochrome P450 2C19
Licensee: Biopredic U.S., Inc.
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2019
License No: L-084-2019
Tech No: E-200-2001
Technology: Chimeric Mouse/human Anti-human ROR1 MAb 2A2
Licensee: Miltenyi Biotec B.V. & Co. KG
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2011
License No: L-086-2011
Tech No: E-097-2009
Technology: FUSED AZEPINONE CYCLIN DEPENDENT KINASE INHIBITORS
Licensee: Alexis Biochemicals Corporation
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2000
License No: L-087-2000
Tech No: E-025-1998
Technology: Method For Preventing Reactogenicity Associated With Administration Of Immunogenic Live Human-Rhesus Rotavirus Composition
Licensee: International Medica Foundation
Exclusivity: Exclusive
Territory: Worldwide
FY: 2003
License No: L-088-2003
Tech No: E-088-2000
Technology: Methods and Devices for Isolation and Analysis of Cellular Protein Content
Licensee: Theranostics Health, LLC
Exclusivity: Nonexclusive
Territory: US
FY: 2007
License No: L-089-2007
Tech No: E-261-1998
Technology: A Single-domain Human Antibody, SD1, Elicits Potent Antitumor Activity By Targeting A Novel Epitope In Mesothelin Close To The Cancer Cell Surface
Licensee: H2bio
Exclusivity: Exclusive
Territory: Worldwide
FY: 2016
License No: L-089-2016
Tech No: E-236-2012
Technology: HUMAN IMMUNODEFICIENCY VIRUSES ASSOCIATED WITH AIDS, A DIAGNOSTIC METHOD FOR AIDS AND PRE-AIDS, A KIT THEREFOR
Licensee: Quest Diagnostics Inc.
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2011
License No: L-091-2011
Tech No: E-317-1984
Technology: Optimization Of Expression Of Human Interleukin-15 (IL-15) And Improved DNA Vector Combinations Of IL-15 And IL-15 Receptor Alpha And Protein Combinations Of Same That Increase Cytokine Stability And Biological Function In Vivo And In Vitro
Licensee: Admune Therapeutics LLC
Exclusivity: Exclusive
Territory: Worldwide
FY: 2012
License No: L-092-2012
Tech No: E-254-2005
Technology: Therapeutic Approach To Neurodegenerative Disorders Using A TFP5-peptide
Licensee: Cogentis Therapeutics, Inc.
Exclusivity: Exclusive
Territory: Worldwide
FY: 2017
License No: L-092-2017
Tech No: E-144-2010
Technology: Development Of A Preventive Vaccine For Filovirus Infection In Primate
Licensee: Crucell Holland BV
Exclusivity: Exclusive
Territory: Worldwide
FY: 2005
License No: L-093-2005
Tech No: E-241-2001
Technology: ACQUIRED IMMUNE DEFICIENCY SYNDROME (AIDS) VIRAL ENVELOPE PRO- TEIN AND METHOD OF TESTING FOR AIDS
Licensee: BioLytical Laboratories, Corp
Exclusivity: Nonexclusive
Territory: US
FY: 2010
License No: L-093-2010
Tech No: E-722-1984
Technology: Methods Of Preparing Lymphocytes That Express Interleukin-12 And Their Use In The Treatment Of Cancer
Licensee: Innovative Cellular Therapeutics
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2020
License No: L-094-2020
Tech No: E-170-2009
Technology: Chimeric Mouse/human Anti-human ROR1 MAb 2A2
Licensee: BioLegend, Inc.
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2012
License No: L-095-2012
Tech No: E-097-2009
Technology: AGONIST AND ANTAGONIST PEPTIDES OF CEA
Licensee: Bavarian Nordic, Inc.
Exclusivity: Exclusive
Territory: Worldwide
FY: 2013
License No: L-095-2013
Tech No: E-099-1996
Technology: AGONIST AND ANTAGONIST PEPTIDES OF CEA
Licensee: Bavarian Nordic, Inc.
Exclusivity: Exclusive
Territory: Worldwide
FY: 2013
License No: L-095-2013
Tech No: E-099-1996
Technology: Compounds And Methods For Treating Brain Injury
Licensee: Astrocyte Pharmaceuticals, Inc
Exclusivity: Exclusive
Territory: Worldwide
FY: 2020
License No: L-097-2020
Tech No: E-138-2017
Technology: Transducing T Cells With And HLA All Restricted CT-RCC HERV-E Reactive TCR To Treat Patients With Advanced Clear Cell Kidney Cancer ( CcRCC)
Licensee: T-Cure Bioscience, Inc.
Exclusivity: Exclusive
Territory: Worldwide
FY: 2018
License No: L-098-2018
Tech No: E-120-2016
Technology: Methods For Pre-conditioning Patients For Cell Therapy
Licensee: Kite Pharma, Inc.
Exclusivity: Exclusive
Territory: Worldwide
FY: 2020
License No: L-099-2020
Tech No: E-282-2016
Technology: Geldanamycin Derivative And Method Of Treating Cancer Using Same
Licensee: InvivoGen
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2005
License No: L-100-2005
Tech No: E-050-2000
Technology: Process for Using Poxviruses as Vectors for Expression of Foreign Genes
Licensee: Pfizer, Inc.
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 1985
License No: L-101-1985
Tech No: E-552-1982
Technology: RECOMBINANT DISULFIDE-STABILIZED POLYPEPTIDE FRAGMENTS HAVING BINDING SPECIFICITY
Licensee: Cambridge Antibody Technology Limited Cambridge, , United Kingdom
Exclusivity: Exclusive
Territory: Worldwide
FY: 2007
License No: L-101-2007
Tech No: E-163-1993
Technology: TUMOR TISSUE MICROARRAYS FOR RAPID MOLECULAR PROFILING
Licensee: Pathology Devices, Inc
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2012
License No: L-101-2012
Tech No: E-002-1998
Technology: Production of Adeno-Associated Virus in Insect Cells
Licensee: LakePharma
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2018
License No: L-104-2018
Tech No: E-325-2001
Technology: T-cell Receptor Targeting The Cancer/testis Antigen KK-LC-1
Licensee: T-Cure Bioscience, Inc.
Exclusivity: Exclusive
Territory: Worldwide
FY: 2020
License No: L-104-2020
Tech No: E-153-2016
Technology: CDNA For Human And Pig Dihydropyrimidine Dehydrogenase
Licensee: IR2Dx
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2010
License No: L-105-2010
Tech No: E-157-1994
Technology: Production of Adeno-Associated Virus in Insect Cells
Licensee: GENETHON
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2012
License No: L-105-2012
Tech No: E-325-2001
Technology: Production of Adeno-Associated Virus in Insect Cells
Licensee: Beat BioTherapeutics Corp.
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2013
License No: L-105-2013
Tech No: E-325-2001
Technology: Antifungal Compound Process
Licensee: Mycovia Pharmaceuticals Inc.
Exclusivity: Exclusive
Territory: Worldwide
FY: 2016
License No: L-105-2016
Tech No: E-020-2016
Technology: Production of Adeno-Associated Virus in Insect Cells
Licensee: uniQure B.V.
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2007
License No: L-107-2007
Tech No: E-325-2001
Technology: Regulating Blood Pressure Through Targeting Thrombospondin-l And CD47
Licensee: Tioma Therapeutics
Exclusivity: Exclusive
Territory: Worldwide
FY: 2010
License No: L-107-2010
Tech No: E-227-2006
Technology: Immunotherapy With In Vitro-Selected Antigen-Specific Lymphocytes After Nonmyeloablative Lymphodepleting Chemotherapy
Licensee: Iovance Biotherapeutics. Inc.
Exclusivity: Exclusive
Territory: Worldwide
FY: 2015
License No: L-107-2015
Tech No: E-275-2002
Technology: A Rugged Sheathless CE-ESI-MS Interface for Sensitive Nano-Flow Operation
Licensee: Beckman Coulter Inc.
Exclusivity: Nonexclusive
Territory: US
FY: 2009
License No: L-108-2009
Tech No: E-307-2002
Technology: Selection Of CD8+ PD-1+, 41BB+ TIM-3+ Or LAG-3+ Cells From Tumor-infiltrating Lymphocytes (TIL) Enriches For Tumor-reactive Cells That Can Be Adoptively Transferred For The Treatment Of Cancer
Licensee: Lion Biotechnologies, Inc.
Exclusivity: Exclusive
Territory: Worldwide
FY: 2015
License No: L-108-2015
Tech No: E-059-2013
Technology: Chimeric Antigen Receptor Targeting Human FLT3
Licensee: ElevateBio
Exclusivity: Exclusive
Territory: Worldwide
FY: 2020
License No: L-108-2020
Tech No: E-133-2016
Technology: Software for CT Colonography Computer Aided Detection
Licensee: iCAD, Inc.
Exclusivity: Nonexclusive
Territory: US
FY: 2006
License No: L-111-2006
Tech No: E-111-2002
Technology: Genetically Stable Live Attenuated Vaccine For Respiratory Syncytial Virus (RSV) With Codon Pair Deoptimized And Codon Pair Optimized Elements
Licensee: Codagenix Inc.
Exclusivity: Exclusive
Territory: Worldwide
FY: 2015
License No: L-111-2015
Tech No: E-080-2013
Technology: MELANOMA ANTIGENS AND THEIR USE IN DIAGNOSTIC AND THERAPEUTIC METHODS
Licensee: Santa Cruz Biotechnology, Inc.
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2006
License No: L-113-2006
Tech No: E-057-1994
Technology: HUMAN GENE RELATED TO BUT DISTINCT FROM EGF RECEPTOR GENE (erbB-2)
Licensee: Ventana Medical Systems, Inc.
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2007
License No: L-113-2007
Tech No: E-555-1985
Technology: Treatment Of Diabetes By Expression Of A Novel NGF/exendin-4 Fusion Protein From The Salivary Gland Epithelia
Licensee: Kriya Therapeutics, Inc.
Exclusivity: Exclusive
Territory: Worldwide
FY: 2020
License No: L-115-2020
Tech No: E-142-2011
Technology: Small Molecule Activators Of Human Pyruvate Kinase
Licensee: Millipore Sigma
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2013
License No: L-116-2013
Tech No: E-326-2008
Technology: A Wild-type Strain Of Genotype 3 Hepatitis E Virus, Its Cell Culture Adapted Progeny, Infectious CDNA Clones Of Each And A Cell Culture System Suitable For Studying Zoonotic Spread Of Hepatitis E
Licensee: Katholieke Universiteit Leuven
Exclusivity: Nonexclusive
Territory: Foreign
FY: 2018
License No: L-116-2018
Tech No: E-074-2011
Technology: Near Infrared Photoimmunotherapy (NIR-PIT) Of Negative Regulatory Foxp3+ (CD4+CD25+) T-cells In Tumors As A Highly Effective Cancer Treatment
Licensee: Aspyrian Therapeutics, Inc.
Exclusivity: Exclusive
Territory: Worldwide
FY: 2017
License No: L-117-2017
Tech No: E-231-2015
Technology: A Wild-type Strain Of Genotype 3 Hepatitis E Virus, Its Cell Culture Adapted Progeny, Infectious CDNA Clones Of Each And A Cell Culture System Suitable For Studying Zoonotic Spread Of Hepatitis E
Licensee: Southern Research Institute
Exclusivity: Nonexclusive
Territory: US
FY: 2020
License No: L-117-2020
Tech No: E-074-2011
Technology: Multivalent Human-Bovine Rotavirus Vaccine
Licensee: Sinovac Biotech, Ltd
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2009
License No: L-118-2009
Tech No: E-015-1998
Technology: Sound Attenuation Canopy (SAC); Reduces Noise Transmitted Through The Suspended Ceiling System Present In Most Office Buildings
Licensee: Transwall
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2011
License No: L-118-2011
Tech No: E-102-2010
Technology: DEVELOPMENT OF MUTATIONS USEFUL FOR ATTENUATING DENGUE VIRUSES AND CHIMERIC DENGUE VIRUSES
Licensee: Fundacao Butantan
Exclusivity: Exclusive
Territory: Foreign
FY: 2009
License No: L-119-2009
Tech No: E-120-2001
Technology: Production of Adeno-Associated Virus in Insect Cells
Licensee: Sangamo Biosciences
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2012
License No: L-120-2012
Tech No: E-325-2001
Technology: Combination Immunotherapy Compositions And Methods
Licensee: GlobeImmune, Inc.
Exclusivity: Exclusive
Territory: Worldwide
FY: 2011
License No: L-121-2011
Tech No: E-184-2009
Technology: Stabilized Wuhan Coronavirus Constructs For Vaccination
Licensee: Noachis Terra Inc.
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2020
License No: L-121-2020
Tech No: E-086-2020
Technology: Laparascopic Ultrasound Transducer Trackable With Magnetics
Licensee: Koninklijke Philips N.V.
Exclusivity: Exclusive
Territory: Worldwide
FY: 2017
License No: L-122-2017
Tech No: E-093-2005
Technology: Exendin-4, GLP-1, GIP And Related Analogs – Optimal Use For Mitigating Neurological Disorders
Licensee: Peptron, Inc.
Exclusivity: Exclusive
Territory: Worldwide
FY: 2018
License No: L-122-2018
Tech No: E-249-2016
Technology: MURINE IL-2RY CDNA AND USES THEREOF
Licensee: Taconic Farm, Inc.
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2008
License No: L-123-2008
Tech No: E-079-1993
Technology: O2-ARYL SUBSTITUTED DIAZENIUMDIOLATES
Licensee: JSK Therapeutics, Inc.
Exclusivity: Exclusive
Territory: Worldwide
FY: 2013
License No: L-124-2013
Tech No: E-093-1996
Technology: Clonal Stable Sf9 Cell Lines Containing Rescueable AAV Vector DNA
Licensee: Generation Bio Co.
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2017
License No: L-124-2017
Tech No: E-241-2010
Technology: Anti-y-H2A Antibody, Fusion Proteins Thereof And Method And Kit For Determining Double-Stranded Breaks
Licensee: Enzo Life Sciences, Inc
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2010
License No: L-126-2010
Tech No: E-142-1999
Technology: Fully-human Heavy-chain-only Anti-B-cell Maturation Antigen Chimeric Antigen Receptors
Licensee: Kite Pharma, Inc.
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2020
License No: L-126-2020
Tech No: E-183-2017
Technology: AGONIST AND ANTAGONIST PEPTIDES OF CEA
Licensee: Bavarian Nordic, Inc.
Exclusivity: Exclusive
Territory: Worldwide
FY: 2011
License No: L-127-2011
Tech No: E-099-1996
Technology: Fully-human Heavy-chain-only Anti-B-cell Maturation Antigen Chimeric Antigen Receptors
Licensee: Kite Pharma, Inc.
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2020
License No: L-127-2020
Tech No: E-183-2017
Technology: Multivalent Human-Bovine Rotavirus Vaccine
Licensee: Biological E. Limited
Exclusivity: Nonexclusive
Territory: Foreign
FY: 2005
License No: L-130-2005
Tech No: E-015-1998
Technology: Anti-Marinobufagenin Antibody (Clone 3EG) And
Licensee: CTS Biopharma LLC
Exclusivity: Exclusive
Territory: US
FY: 2018
License No: L-131-2018
Tech No: E-092-2004
Technology: A Gene Expression Biomarker Panel For Diagnosis Of Acute Ischemic Stroke
Licensee: CereDx Inc.
Exclusivity: Co-Exclusive
Territory: Worldwide
FY: 2017
License No: L-132-2017
Tech No: E-023-2010
Technology: Novel Compounds For Treatment Of Giardiasis
Licensee: Subrimed, Inc
Exclusivity: Exclusive
Territory: Worldwide
FY: 2015
License No: L-134-2015
Tech No: E-211-2010
Technology: Chimeric Rabbit/human Anti-human ROR1 Monoclonal Antibodies With Relevance For Cancer Therapy And Diagnosis-[3 New Chimeric Rabbit/human Anti-ROR1 IgG1 (named R11, R12, And Y31)]
Licensee: Ardeagen Corporation
Exclusivity: Exclusive
Territory: Worldwide
FY: 2016
License No: L-134-2016
Tech No: E-039-2011
Technology: Development Of Modified Hemagglutinin Stem Nanoparticles To Elicit Broad Immune Response To Influenza
Licensee: Emergent Product Development
Gaithersburg, Inc.
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2017
License No: L-135-2017
Tech No: E-066-2014
Technology: MODIFIED CELLS AND METHODS OF THERAPY
Licensee: Intima Bioscience Inc.
Exclusivity: Exclusive
Territory: Worldwide
FY: 2020
License No: L-136-2020
Tech No: E-171-2018
Technology: SEROLOGICAL DETECTION OF ANTIBODIES TO HTLV-III IN SER PATIENTS WITH AIDS AND PRE-AIDS CONDITIONS
Licensee: PerkinElmer Life and Analytical Sciences, Boston, MA, United States
Inc.
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2005
License No: L-141-2005
Tech No: E-317-1984
Technology: MONOCLONAL ANTIBODIES AGAINST THE ALPHA PDGF RECEPTOR AND USES THEREOF
Licensee: ImClone Systems, Inc.
Exclusivity: Exclusive
Territory: Worldwide
FY: 2006
License No: L-142-2006
Tech No: E-040-1993
Technology: Recombinant Vaccines for Influenza and Hepatitis B Virus
Licensee: Transgene S.A.
Exclusivity: Nonexclusive
Territory: US
FY: 2007
License No: L-142-2007
Tech No: E-552-1982
Technology: Treatment Of Cardiovascular Conditions Using Nitrite Therapy
Licensee: Hope Pharmaceuticals
Exclusivity: Exclusive
Territory: Worldwide
FY: 2007
License No: L-143-2007
Tech No: E-254-2003
Technology: Chromatographic Separation of Proteins by Ammonium Sulfate Precipitation
Licensee: CC Biotech, LLC
Exclusivity: Exclusive
Territory: Worldwide
FY: 2007
License No: L-144-2007
Tech No: E-274-1998
Technology: Structure-based Stabilization Of The RSV F Glycoprotein In Its Prefusion Conformation
Licensee: Novartis
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2014
License No: L-144-2014
Tech No: E-081-2013
Technology: Treatment Of Cardiovascular Conditions Using Nitrite Therapy
Licensee: Globin Solutions, Inc.
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2019
License No: L-145-2019
Tech No: E-254-2003
Technology: Treatment Of Cardiovascular Conditions Using Nitrite Therapy
Licensee: Globin Solutions, Inc.
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2019
License No: L-145-2019
Tech No: E-254-2003
Technology: Production and Use of Human NM23 Protein and Antibodies Therefore
Licensee: BD Biosciences – BD PharMingen
Exclusivity: Nonexclusive
Territory: (blank)
FY: 1994
License No: L-146-1994
Tech No: E-234-1989
Technology: Provision Of The Neutral Sugar N-acetyl Nammosamine (ManNAc) For Increased Intracellular Production Of Sialic Acids
Licensee: Leadiant Biosciences, Inc
Exclusivity: Exclusive
Territory: Worldwide
FY: 2018
License No: L-146-2018
Tech No: E-217-2007
Technology: TYPE A PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR) GENE
Licensee: Santa Cruz Biotechnology, Inc.
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2006
License No: L-148-2006
Tech No: E-099-1989
Technology: Novel Delivery Of Packaged RNA In Mammalian Cells
Licensee: Chimeron Bio Corporation
Exclusivity: Exclusive
Territory: Worldwide
FY: 2017
License No: L-148-2017
Tech No: E-264-2011
Technology: Papillomavirus L2 N-terminal Peptides For The Induction Of Broadly Cross-neutralizing Antibodies
Licensee: BravoVax Co., Ltd.
Exclusivity: Exclusive
Territory: Foreign
FY: 2018
License No: L-148-2018
Tech No: E-103-2005
Technology: A Recombinant Vector Expressing Multiple Costimulatory Molecules and Uses Thereof
Licensee: Bavarian Nordic, Inc.
Exclusivity: Exclusive
Territory: Worldwide
FY: 2008
License No: L-149-2008
Tech No: E-256-1998
Technology: DEVELOPMENT OF MUTATIONS USEFUL FOR ATTENUATING DENGUE VIRUSES AND CHIMERIC DENGUE VIRUSES
Licensee: Serum Institute of India PVT. LTD.
Exclusivity: Nonexclusive
Territory: Foreign
FY: 2015
License No: L-149-2015
Tech No: E-120-2001
Technology: The Use Of Leptin For Treating Human Lipotrophy
Licensee: Aegerion Pharmaceuticals, Inc.
Exclusivity: Exclusive
Territory: Worldwide
FY: 2017
License No: L-149-2017
Tech No: E-064-2004
Technology: Stabilized Coronavirus Proteins For Vaccination
Licensee: Medigen Vaccine Biologics Corp
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2020
License No: L-150-2020
Tech No: E-234-2016
Technology: Model For Providing A Patient-specific Diagnosis Of Disease Using Clinical Dataprobability Of Transplant Glomerulopathy
Licensee: DecisionQ Corporation
Exclusivity: Exclusive
Territory: Worldwide
FY: 2012
License No: L-151-2012
Tech No: E-219-2011
Technology: Compositions And Methods For Chitosan Enhanced Immune Response
Licensee: Arko Laboratories Ltd.
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2010
License No: L-153-2010
Tech No: E-311-2006
Technology: Process for Using Poxviruses as Vectors for Expression of Foreign Genes
Licensee: Merial Limited
Exclusivity: Nonexclusive
Territory: US
FY: 2006
License No: L-154-2006
Tech No: E-552-1982
Technology: Structure-based Stabilization Of The RSV F Glycoprotein In Its Prefusion Conformation
Licensee: Icosavax Inc.
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2018
License No: L-155-2018
Tech No: E-081-2013
Technology: Use Of Viral Like Particles (VLPs) In The Development Of A Preventive Vaccine Against Chikungunya
Licensee: Emergent Product Development
Gaithersburg, Inc.
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2020
License No: L-155-2020
Tech No: E-004-2009
Technology: Clearing-enhanced 3D (Ce3D): A Novel Tissue Clearing Method Preserving Cellular Morphology, Reporter Fluorescence, Epitope
Licensee: BioLegend, Inc.
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2020
License No: L-157-2020
Tech No: E-168-2016
Technology: Identification Of Lnc-FANCI-2 As A Biomarker For Diagnosis And Therapy Of HPV Infections With A High-risk Of Progression
Licensee: Mokobio Life Science Group, Inc.
Exclusivity: Co-Exclusive
Territory: US
FY: 2017
License No: L-158-2017
Tech No: E-176-2015
Technology: Anti-Coronavirus Antibodies And Methods Of Use
Licensee: AbCellera Biologics Inc.
Exclusivity: Exclusive
Territory: Worldwide
FY: 2020
License No: L-158-2020
Tech No: E-131-2020
Technology: Treatment Of Cardiovascular Conditions Using Nitrite Therapy
Licensee: Hope Pharmaceuticals
Exclusivity: Exclusive
Territory: Worldwide
FY: 2007
License No: L-159-2007
Tech No: E-254-2003
Technology: Endoluminal Radiofrequency Cauterization System
Licensee: Asthmatx, Inc.
Exclusivity: Nonexclusive
Territory: US
FY: 2010
License No: L-159-2010
Tech No: E-244-2000
Technology: Invention Of Tools For The Subculture Of Embryonic Stem Cells
Licensee: Life Technologies Corporation
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2007
License No: L-160-2007
Tech No: E-272-2005
Technology: Second Generation Integrin Avb3 Antagonists For Use In Imaging And Therapy
Licensee: Advanced Imaging Projects, LLC (AIP)
Exclusivity: Exclusive
Territory: Worldwide
FY: 2018
License No: L-160-2018
Tech No: E-170-2004
Technology: Structure-based Stabilization Of The RSV F Glycoprotein In Its Prefusion Conformation
Licensee: Merck Sharp & Dohme Research Labs.
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2015
License No: L-162-2015
Tech No: E-081-2013
Technology: Novel Peripherally Restricted CB1 Receptor Inverse Agonists For The Treatment Of Diabetes And Obesity
Licensee: Inversago Pharma, Inc
Exclusivity: Exclusive
Territory: Worldwide
FY: 2016
License No: L-162-2016
Tech No: E-282-2012
Technology: Targeted Combination Therapy
Licensee: Aura Biosciences, Inc.
Exclusivity: Exclusive
Territory: Worldwide
FY: 2013
License No: L-164-2013
Tech No: E-184-2016
Technology: A Wild-type Strain Of Genotype 3 Hepatitis E Virus, Its Cell Culture Adapted Progeny, Infectious CDNA Clones Of Each And A Cell Culture System Suitable For Studying Zoonotic Spread Of Hepatitis E
Licensee: Texcell
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2015
License No: L-164-2015
Tech No: E-074-2011
Technology: HUMAN IMMUNODEFICIENCY VIRUS SPECIFIC PROTEOLYTIC ENZYME AND A METHOD FOR ITS SYNTHESIS AND RENATURATION
Licensee: Trinity Biotech, Plc
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 1999
License No: L-165-1999
Tech No: K-446-1987
Technology: Recombinant Vaccines for Influenza and Hepatitis B Virus
Licensee: SillaJen Biotherapeutics, Inc.
Exclusivity: Exclusive
Territory: Worldwide
FY: 2013
License No: L-165-2013
Tech No: E-552-1982
Technology: Chimeric Mouse/human Anti-human ROR1 MAb 2A2
Licensee: EXBIO Praha
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2018
License No: L-165-2018
Tech No: E-097-2009
Technology: Zscan4:
Licensee: Elixirgen, LLC
Exclusivity: Nonexclusive
Territory: (blank)
FY: 2016
License No: L-166-2016
Tech No: E-088-2007
Technology: Codon-optimized Reduced-size ATP7A Complementary DNA For Treatment Of Menkes Disease And Related Copper Transport Disorders
Licensee: Cyprium Therapeutics Inc.
Exclusivity: Exclusive
Territory: Worldwide
FY: 2017
License No: L-167-2017
Tech No: E-062-2015
Technology: CLONE FOR HUMAN MULTIDRUG RESISTANCE GENE
Licensee: Enanta Pharmaceuticals, Inc.
Exclusivity: Nonexclusive
Territory: US
FY: 2015
License No: L-169-2015
Tech No: E-308-1987
Technology: AAV5 AND USES THEREOF
Licensee: BioMarin Pharmaceutical Inc.
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2015
License No: L-170-2015
Tech No: E-127-1998
Technology: Therapeutic Approach To Neurodegenerative Disorders Using A TFP5-peptide
Licensee: AestasRx Inc.
Exclusivity: Exclusive
Territory: Worldwide
FY: 2017
License No: L-170-2017
Tech No: E-144-2010
Technology: Monoclonal Anti-mouse And Anti-human TL1A Antibodies For Diagnostic And Therapeutic Uses
Licensee: Bio X Cell
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2019
License No: L-171-2019
Tech No: E-073-2011
Technology: S9 And C38 Cell Lines Which Are CFBE IB3-1 (IB3 Is A Human Bronchial Epithelial Cell Line) Transfected Cell Lines
Licensee: Johns Hopkins University (JHU)
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2008
License No: L-172-2008
Tech No: E-148-1992
Technology: Development Of A Multimolecular And Multimodular Biomarker Panel For The Early Screening, Molecular Distinction And Clinical Follow-up Of Patients Developing Preeclampsia I HELLP Syndrome And Its Preparation Forpreeclampsia I HELLP Syndrome And Its Preparation For Preclinical Testing
Licensee: Genesis Theranostix Ltd.,
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2019
License No: L-172-2019
Tech No: E-348-2013
Technology: AUTOANTIBODY DETECTION FOR CANCER DIAGNOSTICS
Licensee: BioGemex Ltd.
Exclusivity: Nonexclusive
Territory: Other
FY: 2005
License No: L-178-2005
Tech No: E-081-2004
Technology: Stabilized Coronavirus Proteins For Vaccination
Licensee: BioNTech AG
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2020
License No: L-179-2020
Tech No: E-234-2016
Technology: Wuchereria Bancrofti Specific Molecule For The Immunodiagnosis Of Bancrofitan Filariasis And For Surveillance Following Successful Control Programs
Licensee: InBios International, Inc.
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2014
License No: L-181-2014
Tech No: E-281-2010
Technology: Production of Adeno-Associated Virus in Insect Cells
Licensee: Esteve Pharmaceuticals, S.A.
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2017
License No: L-181-2017
Tech No: E-325-2001
Technology: HUMAN GENE RELATED TO BUT DISTINCT FROM EGF RECEPTOR GENE (erbB-2)
Licensee: Abbott Molecular Inc.
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 1999
License No: L-183-1999
Tech No: E-555-1985
Technology: Scopolamine For The Treatment Of Depression And Anxiety
Licensee: Defender Pharmaceuticals, Inc.
Exclusivity: Exclusive
Territory: Worldwide
FY: 2020
License No: L-185-2020
Tech No: E-175-2004
Technology: Adeno-associated Viral Gene Therapy As A New Treatment For Niemann-Pick Disease Type C
Licensee: Galyatech LLC
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2016
License No: L-186-2016
Tech No: E-185-2014
Technology: Production of Adeno-Associated Virus in Insect Cells
Licensee: Casebia Therapeutics, LLC
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2018
License No: L-186-2018
Tech No: E-325-2001
Technology: Method For Inhibiting The Intestinal Farnesoid X Receptor To Decreases Obesity-Associated Non-Alcoholic Fatty Liver Disease (NAFLD)
Licensee: Heliome Biotech, Inc
Exclusivity: Exclusive
Territory: Worldwide
FY: 2016
License No: L-188-2016
Tech No: E-508-2013
Technology: Stabilization Of Helios-expressing Foxp3+ Human Regulatory T Cells Using Random-sequenced Oligonucleotides
Licensee: Teraimmune Inc.
Exclusivity: Exclusive
Territory: US
FY: 2020
License No: L-188-2020
Tech No: E-279-2011
Technology: CLONING AND EXPRESSION OF HTLV-III DNA
Licensee: ViroGen Corp.
Exclusivity: Nonexclusive
Territory: US
FY: 1998
License No: L-190-1998
Tech No: E-172-1986
Technology: Human T Cell Receptor Targeting HLA-A*11:01-restricted KRASG12D Mutation
Licensee: ZioPharm Oncology, Inc.
Exclusivity: Exclusive
Territory: Worldwide
FY: 2019
License No: L-190-2019
Tech No: E-031-2020
Technology: Stabilized Coronavirus Proteins For Vaccination
Licensee: Meso Scale Diagnostics, LLC (MSD)
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2020
License No: L-190-2020
Tech No: E-234-2016
Technology: Optimization Of Expression Of Multimeric Proteins
Licensee: University of Arkansas
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2015
License No: L-191-2015
Tech No: E-192-2008
Technology: Human IPSC-derived Vascular-related And Hematopoetic Cells For Therapies And Toxicology/drug Screenings
Licensee: XCell Science LLC
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2020
License No: L-195-2020
Tech No: E-342-2013
Technology: Multivalent Human-Bovine Rotavirus Vaccine
Licensee: Serum Institute of India PVT. LTD.
Exclusivity: Nonexclusive
Territory: Foreign
FY: 2005
License No: L-197-2005
Tech No: E-015-1998
Technology: Clonal Stable Sf9 Cell Lines Containing Rescueable AAV Vector DNA
Licensee: Solid Biosciences
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2018
License No: L-199-2018
Tech No: E-241-2010
Technology: Multivalent Human-Bovine Rotavirus Vaccine
Licensee: Wuhan Institute of Biological Products,
Co., Ltd
Exclusivity: Nonexclusive
Territory: Other
FY: 2005
License No: L-200-2005
Tech No: E-015-1998
Technology: Multivalent Human-Bovine Rotavirus Vaccine
Licensee: Shandong Yidu Biotechnology Co., Ltd.
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2018
License No: L-200-2018
Tech No: E-015-1998
Technology: Novel Mesothelin Domain Rabbit Monoclonal Antibodies
Licensee: Navrogen Inc
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2020
License No: L-201-2020
Tech No: E-198-2012
Technology: Isolation Of Novel Broadly Neutralizing Monoclonal Antibodies Against HIV-1 Using Epitope-Specific Glycoprotein Probes To Identify HIV-1 Specific B-Cells
Licensee: International AIDS Vaccine Initiative, Inc. New York, NY, United States
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2020
License No: L-202-2020
Tech No: E-300-2009
Technology: TYPE A PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR) GENE
Licensee: BD Biosciences – BD PharMingen
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 1994
License No: L-203-1994
Tech No: E-099-1989
Technology: MONOCLONAL ANTIBODIES FOR HUMAN THYMIDYLATE SYNTHASE
Licensee: Zymed Laboratories, Inc.
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2001
License No: L-203-2001
Tech No: E-137-1990
Technology: Multivalent Human-Bovine Rotavirus Vaccine
Licensee: Shantha Biotechnics PVT. LTD
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2005
License No: L-203-2005
Tech No: E-015-1998
Technology: HUMAN GENE RELATED TO BUT DISTINCT FROM EGF RECEPTOR GENE (erbB-2)
Licensee: Aurora Biosciences Corporation
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2000
License No: L-206-2000
Tech No: E-555-1985
Technology: Photoimmunotherapy Enhanced Drug Therapy: Immediately Following Photoimmunotherapy The Delivery Of Therapeutic Drugs To The Treated Area S Markedly (~10 Fold) Increased Resulting In Increased Local Concentration Of Drug Without Systemic Side Effects
Licensee: Aspyrian Therapeutics, Inc.
Exclusivity: Exclusive
Territory: Worldwide
FY: 2013
License No: L-208-2013
Tech No: E-205-2010
Technology: Beta1-insensitive T2 Magnetization Preparation Of MR Imaging At High Field
Licensee: General Electric Company
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2017
License No: L-209-2017
Tech No: E-073-2005
Technology: Identification And Characterization Of HLA-A24 Agonist Epitopes Of MUC1-Oncoprotein
Licensee: GlobeImmune, Inc.
Exclusivity: Exclusive
Territory: Worldwide
FY: 2015
License No: L-210-2015
Tech No: E-520-2013
Technology: CDNA ENCODING THE LONG ISOFORM OF THE D2 DOPAMINE RECEPTOR.
Licensee: Panlabs, Inc.
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 1994
License No: L-213-1994
Tech No: E-230-1989
Technology: Resolution Doubling With Digital Confocal Microscopy
Licensee: Yokogawa Electric Corporation
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2018
License No: L-214-2018
Tech No: E-005-2012
Technology: A Synthetic Methylmalonyl-CoA Mutase Transgene For The Treatment Of Mut Class Methylmalonic Acidemia (MMA)
Licensee: Selecta Biosciences, Inc.
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2017
License No: L-216-2017
Tech No: E-243-2012
Technology: Novel Codon-optimized And Tagged Human NPC1 Genes And AAV Vectors For The Treatment Of Niemann-Pick Type C1 Deficiency And Related Conditions
Licensee: StrideBio, Inc.
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2018
License No: L-216-2018
Tech No: E-100-2017
Technology: METHOD FOR CONVECTION ENHANCED DELIVERY OF THERAPEUTIC AGENTS
Licensee: Medicenna Therapeutics, Inc.
Exclusivity: Exclusive
Territory: Worldwide
FY: 2014
License No: L-217-2014
Tech No: E-202-2002
Technology: Dengue Tetravalent Vaccine Containing A Common 30 Nucleotide Deletion In The 3′-UTR Of Dengue Types 1,2,3, And 4, Or Antigenic Chimeric Dengue Viruses 1,2,3, And 4
Licensee: Indian Immunologicals Ltd.
Exclusivity: Nonexclusive
Territory: Foreign
FY: 2016
License No: L-217-2016
Tech No: E-089-2002
Technology: Novel Anti-CD19 Chimeric Antigen Receptors
Licensee: Kite Pharma, Inc.
Exclusivity: Exclusive
Territory: Worldwide
FY: 2016
License No: L-218-2016
Tech No: E-042-2014
Technology: Novel Dopamine D3 Receptor Selective Antagonists/partial Agonists With High Affinity And Metabolic Stability For Treatment Of Neuropsychiatric Disorders
Licensee: Braeburn Pharmaceuticals Inc.
Exclusivity: Exclusive
Territory: Worldwide
FY: 2017
License No: L-220-2017
Tech No: E-053-2016
Technology: Production Of Attenuated Respiratory Syncytial Virus Vaccines Involving Modification Of M2 ORF2
Licensee: Sanofi Pasteur (AVP)
Exclusivity: Exclusive
Territory: Worldwide
FY: 2016
License No: L-221-2016
Tech No: E-194-1999
Technology: Ketone Bodies To Protect Tissues From Damage By Ionizing Radiation
Licensee: TDELTAS Limited
Exclusivity: Exclusive
Territory: Worldwide
FY: 2016
License No: L-222-2016
Tech No: E-258-2012
Technology: Chimeric Antigen Receptor Targeting Human FLT3
Licensee: Senti Biosciences, Inc.
Exclusivity: Exclusive
Territory: Worldwide
FY: 2020
License No: L-222-2020
Tech No: E-133-2016
Technology: Chimeric Antigen Receptors Targeting B-cell Maturation Antigen
Licensee: 2seventy bio
Exclusivity: Exclusive
Territory: Worldwide
FY: 2015
License No: L-224-2015
Tech No: E-040-2012
Technology: RECOMBINANT PSEUDOMONAS EXOTOXINS: CONSTRUCTION OF AN ACTIVE IMMUNOTOXIN WITH LOW SIDE EFFECTS
Licensee: NeoPharm, Inc.
Exclusivity: Exclusive
Territory: Worldwide
FY: 1996
License No: L-226-1996
Tech No: E-385-1986
Technology: Phenyl-substituted Thioacetimide And Sulfinylacetamide Modafinil Derivatives As Monamine Transport Inhibitors: Preparation And Use In The Treatment Of CNS Disorders
Licensee: EncepHeal Therapeutics, Inc
Exclusivity: Exclusive
Territory: Worldwide
FY: 2017
License No: L-226-2017
Tech No: E-073-2013
Technology: Therapeutic Approach To Neurodegenerative Disorders Using A TFP5-peptide
Licensee: Great Lakes Neuroscience Inc.
Exclusivity: Exclusive
Territory: Worldwide
FY: 2016
License No: L-229-2016
Tech No: E-144-2010
Technology: Nutritional Supplement to Treat Macular Degeneration
Licensee: Bausch & Lomb, Inc.
Exclusivity: Exclusive
Territory: Worldwide
FY: 2002
License No: L-230-2002
Tech No: E-220-2001
Technology: Preparation Of R,R-fenoterol And R,R-fenoterol Analogues And Their Use In Congestive Heart Failure
Licensee: PAZ Pharmaceuticals
Exclusivity: Exclusive
Territory: Worldwide
FY: 2020
License No: L-230-2020
Tech No: E-205-2006
Technology: Chimeric Antigen Receptors Targeting B-cell Maturation Antigen
Licensee: Thirsty Brook Bioscience, Inc.
Exclusivity: Exclusive
Territory: Worldwide
FY: 2015
License No: L-231-2015
Tech No: E-040-2012
Technology: Molecular Diagnosis Of Lymphoma Subtypes Using Formalin-fixed, Paraffin-embedded Biopsy Specimens
Licensee: NanoString Technologies Inc.
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2014
License No: L-232-2014
Tech No: E-750-2013
Technology: Agents That Bind to and Inhibit Human Cytochrome P450 2A6
Licensee: XenoTech, LLC
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2000
License No: L-234-2000
Tech No: E-150-1998
Technology: Chimeric Antigen Receptors Targeting B-cell Maturation Antigen
Licensee: Cartesian Therapeutics, Inc.
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2019
License No: L-239-2019
Tech No: E-040-2012
Technology: Human IPSC-derived Vascular-related And Hematopoetic Cells For Therapies And Toxicology/drug Screenings
Licensee: StemCell Technologies Inc.
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2016
License No: L-243-2016
Tech No: E-342-2013
Technology: Cell Line ( 8E5 ) Producing AIDS Viral Antigens Without Producing Infectious Viral Particles.
Licensee: BBI-Biotech Research Laboratories, Inc.
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 1994
License No: L-245-1994
Tech No: E-471-1985
Technology: Cell Line ( 8E5 ) Producing AIDS Viral Antigens Without Producing Infectious Viral Particles.
Licensee: BBI-Biotech Research Laboratories, Inc.
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 1994
License No: L-245-1994
Tech No: E-471-1985
Technology: 4-Phenylpiperazine Derivatives With Functionalized Linkers As Dopamine D3 Receptor Selective Ligands With Drug Abuse
Therapeutic Potential
Licensee: Braeburn Pharmaceuticals Inc.
Exclusivity: Exclusive
Territory: Worldwide
FY: 2017
License No: L-245-2017
Tech No: E-128-2006
Technology: Simple, Quantitative, And Highly Sensitive Antibody Detection For Lyme Disease
Licensee: InBios International, Inc.
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2015
License No: L-248-2015
Tech No: E-036-2010
Technology: New Fluorinated DREADD Actuators And Ligands Suitable For PET Imaging
Licensee: Hello Bio Ltd.
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2018
License No: L-250-2018
Tech No: E-023-2018
Technology: Stabilized Coronavirus Proteins For Vaccination
Licensee: Thermo Fisher Scientific Inc.
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2020
License No: L-250-2020
Tech No: E-234-2016
Technology: 0
Licensee: Thermo Fisher Scientific Inc.
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2020
License No: L-251-2020
Tech No:
Technology: Multivalent Human-Bovine Rotavirus Vaccine
Licensee: Sun Biotech Pte., Ltd
Exclusivity: Nonexclusive
Territory: Foreign
FY: 2015
License No: L-253-2015
Tech No: E-015-1998
Technology: Genotype-specific Vaccination Against BK Polyomavirus
Licensee: BioE Holdings Inc.
Exclusivity: Exclusive
Territory: Worldwide
FY: 2019
License No: L-255-2019
Tech No: E-168-2011
Technology: Resolution Doubling With Digital Confocal Microscopy
Licensee: VisiTech International
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2014
License No: L-256-2014
Tech No: E-005-2012
Technology: Novel Peripherally Restricted CB1 Receptor Inverse Agonists For The Treatment Of Diabetes And Obesity
Licensee: Inversago Pharma, Inc
Exclusivity: Exclusive
Territory: Worldwide
FY: 2019
License No: L-257-2019
Tech No: E-282-2012
Technology: Recombinant Vaccines for Influenza and Hepatitis B Virus
Licensee: GeoVax, Inc.
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2020
License No: L-257-2020
Tech No: E-552-1982
Technology: Beta1-insensitive T2 Magnetization Preparation Of MR Imaging At High Field
Licensee: Siemens Healthcare GmbH
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2018
License No: L-258-2018
Tech No: E-073-2005
Technology: Improved Methods Of Manufacturing Peptide-Based Vaccines
Licensee: Avidea Technologies
Exclusivity: Exclusive
Territory: Worldwide
FY: 2019
License No: L-258-2019
Tech No: E-191-2018
Technology: Non-aggregating Heptamethine Cyanine Fluorophores For In Vivo Imaging
Licensee: Tocris Bioscience
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2020
License No: L-258-2020
Tech No: E-046-2019
Technology: HLA Class-II Restricted DPB1*03:01 T-cell Receptors Against The KRASG12V Mutation”
Licensee: Kite Pharma, Inc.
Exclusivity: Exclusive
Territory: Worldwide
FY: 2016
License No: L-259-2016
Tech No: E-088-2020
Technology: Novel Anti-CD19 Chimeric Antigen Receptors
Licensee: CRISPR Therapeutics AG
Exclusivity: Nonexclusive
Territory: (blank)
FY: 2017
License No: L-259-2017
Tech No: E-042-2014
Technology: Stabilized Coronavirus Proteins For Vaccination
Licensee: Sanofi Pasteur (AVP)
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2020
License No: L-262-2020
Tech No: E-234-2016
Technology: Treatment Of Autoimmune Xerostomia By AAV2 Mediated Gene Transfer Of Aquaporin 1 To Salivary Gland Epithelia
Licensee: MeiraGTx, LLC
Exclusivity: Exclusive
Territory: (blank)
FY: 2018
License No: L-263-2018
Tech No: E-139-2011
Technology: A Fully Automated System For Quantitative Myocardial Perfusion Pixel Mapping And Machine Diagnosis To Detect Ischemic Heart Disease With First-pass Perfusion Cardiac Magnetic Resonance Imaging
Licensee: Corstem Inc.
Exclusivity: Exclusive
Territory: Worldwide
FY: 2018
License No: L-264-2018
Tech No: E-219-2018
Technology: Methanocarba Analogues of Purine And Pyrimidine Nucleosides And Nucleotides as Ligands For P1 And P2 Receptors.
Licensee: Tocris Cookson Ltd.
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2002
License No: L-265-2002
Tech No: E-176-1999
Technology: Methods For Producing Autologous T Cells Useful To Treat B Cell Malignancies And Other Cancers
Licensee: Kite Pharma, Inc.
Exclusivity: Exclusive
Territory: Worldwide
FY: 2016
License No: L-268-2016
Tech No: E-234-2014
Technology: Formulation of Boronic Acid Compounds
Licensee: Millennium Pharmaceuticals, Inc.
Exclusivity: Exclusive
Territory: Worldwide
FY: 2001
License No: L-271-2001
Tech No: E-116-2001
Technology: COMPOSITIONS AND METHODS FOR IDENTIFYING AND TESTING TYROSINE KINASE SUBSTRATES AND THEIR AGONISTS AND ANTAGONISTS (As Filed)
Licensee: BioSource International
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2002
License No: L-271-2002
Tech No: E-010-1998
Technology: Nucleic Acids And Pepties Of Human Immunodeficiency Virus Type-1 (HIV-1).
Licensee: Novartis Vaccines & Diagnostics
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2014
License No: L-273-2014
Tech No: E-317-1984
Technology: Selection Of CD8+ PD-1+, 41BB+ TIM-3+ Or LAG-3+ Cells From Tumor-infiltrating Lymphocytes (TIL) Enriches For Tumor-reactive Cells That Can Be Adoptively Transferred For The Treatment Of Cancer
Licensee: Cellular Biomedicine Group, Inc (CBMG)
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2018
License No: L-274-2018
Tech No: E-059-2013
Technology: Assay System And Composition Of Multi-domain Amphipathic Helical Peptides For The Treatment Of Atherosclerosis.
Licensee: Hartis-Pharma Sarl
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2018
License No: L-275-2018
Tech No: E-114-2004
Technology: Custom Lymphoid Malignancy Diagnositc DNA MIcroarray -Oligo Probes And Lymphoma Survival Prdiction Algorithm
Licensee: NanoString Technologies Inc.
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2014
License No: L-276-2014
Tech No: E-108-2004
Technology: Novel Peripherally Restricted CB1 Receptor Inverse Agonists For The Treatment Of Diabetes And Obesity
Licensee: Vital Spark Inc.
Exclusivity: Exclusive
Territory: Worldwide
FY: 2017
License No: L-276-2017
Tech No: E-282-2012
Technology: Evans Blue Attachment Enhances Somatostatin Receptor Imaging And Radiotherapy
Licensee: Molecular Targeting Technologies, Inc
Exclusivity: Exclusive
Territory: Worldwide
FY: 2018
License No: L-276-2018
Tech No: E-150-2016
Technology: A Varicella-Zoster Vaccine Mutant Impaired For Latency But Not For Replication
Licensee: Biological E Limited
Exclusivity: Nonexclusive
Territory: Foreign
FY: 2018
License No: L-277-2018
Tech No: E-217-2004
Technology: Method For The Detection Of A Subdural Hematoma For Use In A Handheld Hematoma Detector And Discriminator.
Licensee: ArcheOptix Biomedical, Inc.
Exclusivity: Exclusive
Territory: Worldwide
FY: 2014
License No: L-280-2014
Tech No: E-010-2010
Technology: Long-Acting Insulinotropic Peptides And Uses Thereof
Licensee: Peptron, Inc.
Exclusivity: Exclusive
Territory: Worldwide
FY: 2014
License No: L-281-2014
Tech No: E-049-2001
Technology: Detection And Quantification of Cripto-1
Licensee: Beacon Biomedical, Inc.
Exclusivity: Exclusive
Territory: Worldwide
FY: 2014
License No: L-282-2014
Tech No: E-290-2000
Technology: Custom Lymphoid Malignancy Diagnositc DNA MIcroarray -Oligo Probes And Lymphoma Survival Prdiction Algorithm
Licensee: British Columbia Cancer Agency
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2014
License No: L-289-2014
Tech No: E-108-2004
Technology: Clonal Stable Sf9 Cell Lines Containing Rescueable AAV Vector DNA
Licensee: CELiD Biotechnologies, Inc.
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2017
License No: L-294-2017
Tech No: E-241-2010
Technology: Production of Adeno-Associated Virus in Insect Cells
Licensee: CELiD Biotechnologies, Inc.
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2017
License No: L-295-2017
Tech No: E-325-2001
Technology: N6, A Novel, Broad, Highly Potent HIV-specific Antibody
Licensee: GlaxoSmithKline Intellectual Property
Limited
Exclusivity: Exclusive
Territory: Worldwide
FY: 2019
License No: L-298-2019
Tech No: E-131-2015
Technology: CANNABINOIDS AS ANTIOXIDANTS AND NEUROPROTECTANTS
Licensee: KannaLife Sciences, Inc.
Exclusivity: Nonexclusive
Territory: (blank)
FY: 2014
License No: L-302-2014
Tech No: E-287-1997
Technology: Further Modifications To HIV Neutralizing Antibodies To Improve Function
Licensee: TaiMed Biologics USA, Inc
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2019
License No: L-303-2019
Tech No: E-051-2012
Technology: A Novel Method To Isolate The Paired Sequences Of Neoantigen-specific T Cell Receptors
Licensee: Intellia Therapeutics, Inc.
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2019
License No: L-304-2019
Tech No: E-067-2017
Technology: Adoptive T Cell Therapy Using Rapamycin-Resistant, CD28 Co-Stimulated Th1/Th2 And Tc1/Tc2 Cells
Licensee: Rapa Therapeutics LLC
Exclusivity: Nonexclusive
Territory: (blank)
FY: 2017
License No: L-308-2017
Tech No: E-063-2003
Technology: NOVEL IMMUNOTOXINS AND METHODS OF INDUCING IMMUNE TOLERANCE
Licensee: Angimmune LLC
Exclusivity: Exclusive
Territory: Worldwide
FY: 2014
License No: L-313-2014
Tech No: E-044-1997
Technology: Small Molecules (Derivatives Of Hydroxylamine) As Therapeutic Agents For Disorders Caused By Thioesterase Deficiency
Licensee: Circumvent Pharm
Exclusivity: Exclusive
Territory: Worldwide
FY: 2019
License No: L-313-2019
Tech No: E-157-2011
Technology: Radiotherapy And Imaging Agent Based On Peptide Conjugated To Novel Evans Blue Derivatives With Long Half-life And High Accumulation In Target Tissue
Licensee: Molecular Targeting Technologies, Inc
Exclusivity: Exclusive
Territory: Worldwide
FY: 2019
License No: L-315-2019
Tech No: E-150-2016
Technology: Stabilized Single Human CD4 Domains And Fusion Proteins As Exceptionally Potent HIV-1 Entry Inhibitors
Licensee: Lentigen Corporation
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2017
License No: L-317-2017
Tech No: E-033-2013
Technology: Novel, Potent And Selective A3 Adenosine Receptor Antagonists
Licensee: FM Therapeutics Co., Ltd.
Exclusivity: Exclusive
Territory: Worldwide
FY: 2017
License No: L-324-2017
Tech No: E-109-2006
Technology: High-affinity Mouse Monoclonal Antibodies To Glypican-3 For Liver Cancer Therapy And Diagnosis
Licensee: Diagnostic BioSystems
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2017
License No: L-325-2017
Tech No: E-136-2012
Technology: Multi-dimensional Liquid Chromatography Separation System
Licensee: Shimadzu Corporation
Exclusivity: Exclusive
Territory: Worldwide
FY: 2002
License No: L-327-2002
Tech No: E-088-2002
Technology: Production of Adeno-Associated Virus in Insect Cells
Licensee: Voyager Therapeutics, Inc.
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2014
License No: L-327-2014
Tech No: E-325-2001
Technology: Novel Mesothelin Domain Rabbit Monoclonal Antibodies
Licensee: Diagnostic BioSystems
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2017
License No: L-327-2017
Tech No: E-198-2012
Technology: High-affinity Mouse Monoclonal Antibodies To Glypican-3 For Liver Cancer Therapy And Diagnosis
Licensee: Abpro
Exclusivity: Exclusive
Territory: Worldwide
FY: 2017
License No: L-329-2017
Tech No: E-136-2012
Technology: Novel Robust Production Process Of High Purity Polio Virus And Polio Virus Variants (PVS-RIPO)
Licensee: Istari Oncology Inc.
Exclusivity: Exclusive
Territory: Worldwide
FY: 2017
License No: L-331-2017
Tech No: E-267-2014
Technology: Wuchereria Bancrofti Specific Molecule For The Immunodiagnosis Of Bancrofitan Filariasis And For Surveillance Following Successful Control Programs
Licensee: PATH Vaccine Solutions
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2014
License No: L-333-2014
Tech No: E-281-2010
Technology: Cyclopentane-Peptide Nucleic Acids For Qualitative And Quantitative Detection Of Nucleic Acids
Licensee: AltraTech Ltd
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2017
License No: L-339-2017
Tech No: E-260-2012
Technology: A HIGHLY EFFICACY, HIGH YIELD PERTUSSIS VACCINE AND METHOD FOR MAKING SAME.
Licensee: List Biological Laboratories, Inc.
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2001
License No: L-343-2001
Tech No: E-159-1999
Technology: Live-Attenuated Or Inactivated Bivalent Vaccines That Confer Dual Protection Against Rabies And Ebola Viruses
Licensee: Exxell BIO, inc
Exclusivity: Exclusive
Territory: Other
FY: 2014
License No: L-346-2014
Tech No: E-032-2011
Technology: AAV5 AND USES THEREOF
Licensee: Takara Bio Inc.
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 2014
License No: L-353-2014
Tech No: E-127-1998
Technology: Human Papilloma Virus Immunogenic Peptides
Licensee: Georgia Health Sciences University
Research Institute, Inc.
Exclusivity: Exclusive
Territory: Worldwide
FY: 2014
License No: L-356-2014
Tech No: E-126-2001
Technology: SEROLOGICAL DETECTION OF ANTIBODIES TO HTLV-III IN SER PATIENTS WITH AIDS AND PRE-AIDS CONDITIONS
Licensee: BioMerieux, Inc.
Exclusivity: Nonexclusive
Territory: Worldwide
FY: 1991
License No: L-745-1991
Tech No: E-317-1984